Oxiracetam

Description

Oxiracetam Overview

Oxiracetam is a synthetic nootropic research compound belonging to the racetam family. Racetams share a common chemical backbone based on a 2-pyrrolidone structure and have been widely studied in laboratory environments for their interactions with neuronal signaling systems.

Within racetam research literature, oxiracetam is frequently discussed alongside piracetam and aniracetam, as these compounds have been examined for their influence on AMPA-type glutamate receptors in experimental models. Research suggests that this interaction may influence receptor signaling activity and synaptic communication pathways.

Chemical and Molecular Properties

PubChem CID	4626
Molecular Formula	C6H10N2O3
Molecular Weight	158.16 g/mol
Synonyms	ISF 2522, Neuractiv, Neuromet, CGP 21690E, GNF-PF-1005
IUPAC	2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide
CAS	62613-82-5
Labeling	Research Use Only (RUO), not for human or animal consumption
Chemical Structure Depiction
Purity	99% Purity
Classification	Research Use Only (RUO), not for human or animal consumption
Storage Temperature	Store in a controlled room temperature, typically between 15°C and 30°C (59°F to 86°F)

Mechanisms of Action

The precise biochemical mechanisms of oxiracetam remain an active area of investigation. However, several potential mechanisms have been reported in experimental studies, including:

• Modulation of AMPA-sensitive glutamate receptors in neuronal models
• Influence on acetylcholine-related signaling pathways
• Effects on neuronal energy metabolism, including glucose utilization
• Investigation of interactions with 1,4-dihydropyridine receptor binding sites in the cerebral cortex
• Observations related to cell survival signaling pathways in neuronal cultures

Potential Research Applications

Oxiracetam has been referenced in scientific literature examining neuronal signaling pathways, synaptic communication, and cellular responses within neurological systems. Researchers may investigate this compound in controlled laboratory environments to better understand its biochemical interactions and molecular characteristics.

Neurotransmitter Signaling Studies

Oxiracetam has been explored in research examining glutamatergic and cholinergic signaling pathways. Laboratory studies may investigate how the compound interacts with neurotransmitter systems associated with synaptic transmission and neuronal communication.

Receptor Modulation Research

Some experimental models have examined oxiracetam in the context of AMPA-type glutamate receptor activity. Researchers may utilize the compound to study receptor modulation, ligand-receptor interactions, and downstream intracellular signaling pathways.

Synaptic Plasticity and Neural Network Investigations

Oxiracetam may be included in laboratory studies evaluating synaptic plasticity mechanisms, including processes related to neuronal connectivity and signal transmission within neural circuits.

Disclaimer

This information is for educational purposes only and not medical advice. Products are for research use only. Research must follow IRB or IACUC guidelines. Verify information independently before purchasing. By ordering, you agree to our Terms and Conditions. If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co

ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY, not for veterinary or human use

References:

1. Bottini, G., Vallar, G., Cappa, S., Monza, G. C., Scarpini, E., Baron, P., Cheldi, A., & Scarlato, G. (1992). Oxiracetam in dementia: a double-blind, placebo-controlled study. Acta Neurologica Scandinavica, 86(3), 237-241. https://doi.org/10.1111/j.1600-0404.1992.tb05077.x
2. Saletu, B., Linzmayer, L., GrUNberger, J., & Pietschmann, H. (1985). Double-Blind, Placebo-Controlled, Clinical, Psychometric and Neurophysiological Investigations with Oxiracetam in the Organic Brain Syndrome of Late Life. Neuropsychobiology, 13(1-2), 44-52. https://doi.org/10.1159/000118161
3. Europe PMC. (n.d.). Europe PMC. https://europepmc.org/article/med/3594458